Immutep banks ~A$856,669 R&D tax rebate, extending cash runway into 2028
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has received an A$856,669 cash rebate under the Australian Federal Government’s R&D Tax Incentive program, relating to eligible R&D expenditure incurred in the 2025 fiscal year. The receipt followed AusIndustry’s approval of an Advance overseas finding, which allowed certain of Immutep’s overseas R&D activities to qualify for the incentive alongside its eligible Australian activities.
The non-dilutive funding will be directed towards advancing the company’s two product candidates, efti and IMP761. Immutep’s expected cash reach extends into H1 CY2028.
When big ASX news breaks, our subscribers know first
Understanding R&D tax incentives — why non-dilutive funding matters for biotech investors
Australia’s R&D Tax Incentive program provides eligible companies with a refundable cash offset based on qualifying R&D expenditure. In practice, a clinical-stage biotech that spends on research activities receives a portion of that spend back as a cash rebate from the government.
The term “non-dilutive” simply means the funding is received without issuing new shares. For existing shareholders, this is a meaningful distinction: the company replenishes its cash position without reducing the ownership percentage of current investors.
For a company like Immutep, which is developing its product candidates, non-dilutive inflows of this kind help extend the operational runway and reduce pressure to raise capital from markets in the near term.
A multi-jurisdictional R&D funding base
Immutep draws on R&D tax incentive programs across three jurisdictions, reflecting the geographic spread of its operations:
- Australia: Federal R&D Tax Incentive — current receipt of A$856,669 for FY2025 eligible expenditure, supported by an Advance overseas finding
- France: French CIR (Crédit d’Impôt Recherche) — received through subsidiary Immutep S.A.S. for eligible R&D expenditure conducted in the European Union
- Germany: Forschungszulage — available through subsidiary Immutep GmbH for qualifying internal R&D personnel costs; first payment received in Q4 FY26; any future payments remain subject to the statutory application, assessment and review process, with amount and timing uncertain
| Jurisdiction | Program Name | Status |
|---|---|---|
| Australia | Federal R&D Tax Incentive | Received — A$856,669 for FY2025 |
| France | Crédit d’Impôt Recherche (CIR) | Active — via Immutep S.A.S. |
| Germany | Forschungszulage | First payment received Q4 FY26; future payments uncertain |
What this means for Immutep’s investment case
The rebate feeds directly into Immutep’s ongoing R&D programmes for efti and IMP761, supporting continued clinical activity without drawing on equity markets. The headline investor takeaway is the cash reach: the company’s expected cash reach extends to H1 CY2028, which reduces near-term capital raise pressure.
IMP761 Phase I results presented at EULAR 2026 confirmed a favourable safety and tolerability profile and statistically significant immunosuppressive activity, establishing the LAG-3 agonist as the only candidate of its class currently in clinical development.
Recurring access to non-dilutive government incentives across Australia, France, and Germany provides a supplementary funding layer that complements Immutep’s broader financing strategy, though these inflows are modest relative to clinical-stage operating costs and should be viewed accordingly.
Alongside non-dilutive government incentives, the FDA Orphan Drug Designation for efti in soft tissue sarcoma provides a parallel form of capital efficiency, covering tax credits on clinical trial costs and exempting Immutep from FDA application fees on that indication.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment news breaks. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.